DealForma

Early-stage biopharma funding in 2026 YTD remained concentrated in biologics and cancer, although overall investment is running below 2025 levels in several major categories. Find additional biopharma deal data and charts on DealForma.

Biopharma venture rounds grew larger across most development stages in 2026 YTD. Find additional biopharma deal data and charts on DealForma.

Later-stage biopharma venture financing continued to attract more capital than first-round funding in 2026 YTD. Find additional biopharma deal data and charts on DealForma.

UK and Swiss biopharma led European venture fundraising through Q3 2026. Find additional biopharma deal data and charts on DealForma.

Biopharma venture activity remained concentrated in the largest U.S. life sciences hubs through Q3 2026. Find additional biopharma deal data and charts on DealForma.

AI/ML has become one of the largest destinations for biopharma venture capital in 2025–2026 YTD. Find additional biopharma deal data and charts on DealForma.

Biopharma venture activity slowed across financing stages in Q3 2026. Find additional biopharma deal data and charts on DealForma.

Biopharma venture investment pulled back in Q3 2026 after a stronger first half. Find additional biopharma deal data and charts on DealForma.

Discovery-stage licensing in 2025–2026 YTD has been concentrated around antibodies, small molecules, and AI/ML platforms. Find additional biopharma deal data and charts on DealForma.

AI-based target and drug discovery licensing continued to climb in 2026. Find additional biopharma deal data and charts on DealForma.